Assess the Diagnostic Potential of Several Significant Biomarkers for Parkinson's Disease
Downloads
Parkinson's disease (PD), a neurodegenerative disorder, is associated with altered blood biochemistry, this study investigates key biomarkers like dopamine, alpha-synuclein, Tau protein, TNF, beta-amyloid, IL-6, copper, and iron in both healthy individuals and PD patients, the study was conducted on (90) for both healthy and patients, both males and females were between the ages of 50 and 85 years old. The findings show that PD patients have significantly lower levels of dopamine (19.40 ± 0.82 pg/mL) than healthy people (31.58 ± 1.07 pg/mL, p < 0.01), which demonstrates its part in the disease's pathogenesis.; elevated levels of Tau protein (41.58 ± 2.97 ng/L vs. 9.85 ± 3.6 ng/L, p < 0.01) and alpha-synuclein (47.31 ± 1.91 pg/mL vs. 25.84 ± 2.07 pg/mL, p < 0.01) suggest neurodegenerative involvement; PD patients have higher levels of the markers of inflammation TNF and IL-6. further indicate neuroinflammation; and beta-amyloid levels are significantly higher in PD patients (168.78 ± 0.27 pg/mL) than in controls (80.65 ± 1.13 pg/mL, p < 0.01), highlighting the role of amyloid pathology in disease progression. A gender-based investigation showed only small variations, with females having slightly greater levels of alpha-synuclein and IL-6. The age-dependent character of PD-related biochemical alterations is further supported by age-stratified data in PD patients, which indicate gradual decreases in dopamine and iron along with rising levels of Tau protein and alpha-synuclein across age groups.
1. Busnatu, Ș. and A.G. Niculescu, Clinical Applications of Artificial Intelligence-An Updated Overview. 2022. 11(8).
2. Checkoway, H., J.I. Lundin, and S.N. Kelada, Neurodegenerative diseases. IARC scientific publications, 2011(163): p. 407-419.
3. Beitz, J.M., Parkinson's disease: a review. Front Biosci (Schol Ed), 2014. 6(1): p. 65-74.
4. Zhao, J., et al., The molecular mechanism of aging and the role in neurodegenerative diseases. Heliyon, 2024. 10(2): p. e24751.
5. Cramb, K.M.L., et al., Impaired dopamine release in Parkinson’s disease. Brain, 2023. 146(8): p. 3117-3132.
6. Steiner, J.A., E. Quansah, and P. Brundin, The concept of alpha-synuclein as a prion-like protein: ten years after. Cell Tissue Res, 2018. 373(1): p. 161-173.
7. Mahlknecht, P., K. Seppi, and W. Poewe, The Concept of Prodromal Parkinson's Disease. J Parkinsons Dis, 2015. 5(4): p. 681-97.
8. Tremblay, C., P. Durand Martel, and J. Frasnelli, Trigeminal system in Parkinson's disease: A potential avenue to detect Parkinson-specific olfactory dysfunction. Parkinsonism Relat Disord, 2017. 44: p. 85-90.
9. Mei, J., C. Desrosiers, and J. Frasnelli, Machine Learning for the Diagnosis of Parkinson's Disease: A Review of Literature. Front Aging Neurosci, 2021. 13: p. 633752.
10. Hijaz, B.A. and L.A. Volpicelli-Daley, Initiation and propagation of α-synuclein aggregation in the nervous system. Mol Neurodegener, 2020. 15(1): p. 19.
11. Ren, J., et al., Plasma α-synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson's disease. 2022. 161(6): p. 506-515.
12. Jankovic, J., Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry, 2008. 79(4): p. 368-76.
13. Chang, C.W., et al., Plasma and Serum Alpha-Synuclein as a Biomarker of Diagnosis in Patients With Parkinson's Disease. Front Neurol, 2019. 10: p. 1388.
14. Stefanis, L., α-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med, 2012. 2(2): p. a009399.
15. Chojdak-Łukasiewicz, J., et al., Plasma tau protein and Aβ42 level as markers of cognitive impairment in patients with Parkinson's disease. Adv Clin Exp Med, 2020. 29(1): p. 115-121.
16. Youssef, P., et al., Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting. Sci Rep, 2023. 13(1): p. 5217.
17. Molinuevo, J.L., et al., Current state of Alzheimer's fluid biomarkers. Acta Neuropathol, 2018. 136(6): p. 821-853.
18. Dufek, M., et al., Interleukin-6 May Contribute to Mortality in Parkinson’s Disease Patients: A 4-Year Prospective Study. Parkinson's Disease, 2015. 2015(1): p. 898192.
19. Chen, J., et al., The molecular mechanisms of copper metabolism and its roles in human diseases. 2020. 472(10): p. 1415-1429.
20. Foley, P.B., D.J. Hare, and K.L. Double, A brief history of brain iron accumulation in Parkinson disease and related disorders. 2022. 129(5-6): p. 505-520.
21. Schirinzi, T., et al., Tau and Amyloid-β Peptides in Serum of Patients With Parkinson's Disease: Correlations With CSF Levels and Clinical Parameters. Front Neurol, 2022. 13: p. 748599.
22. Busra, M., Y. Syafrita, and H. Permana, Relationship of Serum Tau Levels with Cognitive Functions and Factors Affecting The Cognitive Function Decrease in Parkinson's Disease Patients. Bioscientia Medicina : Journal of Biomedicine and Translational Research, 2021. 5: p. 513-519.
23. Caranci, G., et al., Gender differences in Parkinson's disease: focus on plasma α-synuclein. J Neural Transm (Vienna), 2013. 120(8): p. 1209-15.
24. Nicoletti, A., et al., Gender effect on non-motor symptoms in Parkinson's disease: are men more at risk? Parkinsonism Relat Disord, 2017. 35: p. 69-74.
25. Pigott, K., et al., Longitudinal study of normal cognition in Parkinson disease. Neurology, 2015. 85(15): p. 1276-82.
26. Berry, A.S. and V.D. Shah, Aging Affects Dopaminergic Neural Mechanisms of Cognitive Flexibility. 2016. 36(50): p. 12559-12569.
27. Karrer, T.M., et al., Reduced dopamine receptors and transporters but not synthesis capacity in normal aging adults: a meta-analysis. Neurobiology of Aging, 2017. 57: p. 36-46.
28. Bjørklund, G., et al., The glutathione system in Parkinson’s disease and its progression. Neuroscience & Biobehavioral Reviews, 2021. 120: p. 470-478.
29. Zeidan, R.S., et al., Iron homeostasis in older adults: balancing nutritional requirements and health risks. The Journal of nutrition, health and aging, 2024. 28(5): p. 100212.
30. Hall, S., et al., Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease. Mov Disord, 2016. 31(6): p. 898-905.
31. Pichet Binette, A., et al., Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease. Nature Communications, 2022. 13(1): p. 6635.
32. Mollenhauer, B., et al., Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology, 2017. 89(19): p. 1959-1969.
33. Kordower, J.H., et al., Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain, 2013. 136(Pt 8): p. 2419-31.
34. Liu, T.-W., C.-M. Chen, and K.-H. Chang, Biomarker of Neuroinflammation in Parkinson’s Disease. International Journal of Molecular Sciences, 2022. 23(8): p. 4148.
35. Du, G., et al., Dynamics of Nigral Iron Accumulation in Parkinson's Disease: From Diagnosis to Late Stage. Mov Disord, 2022. 37(8): p. 1654-1662.
36. Li, X., et al., Association between cigarette smoking and Parkinson's disease: A meta-analysis. Arch Gerontol Geriatr, 2015. 61(3): p. 510-6.
37. Barnes, P.J., Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol, 2016. 138(1): p. 16-27.
38. Rogers, G.B., et al., From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Molecular Psychiatry, 2016. 21(6): p. 738-748.
39. You, M., et al., The gut microbiota–brain axis in neurological disorders. MedComm, 2024. 5(8): p. e656.
40. Zhang, H., et al., Implications of Gut Microbiota in Neurodegenerative Diseases. Front Immunol, 2022. 13: p. 785644.
